Published in Immunity on April 18, 2013
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
A Single miRNA-mRNA Interaction Affects the Immune Response in a Context- and Cell-Type-Specific Manner. Immunity (2015) 1.68
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Induction of Multiple miR-200/182 Members in the Brains of Mice Are Associated with Acute Herpes Simplex Virus 1 Encephalitis. PLoS One (2017) 1.39
Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology (2014) 1.23
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene (2015) 1.16
Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology (2015) 1.11
Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res (2014) 1.06
MicroRNA-directed program of cytotoxic CD8+ T-cell differentiation. Proc Natl Acad Sci U S A (2013) 1.04
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov (2016) 1.03
MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer (2014) 0.99
Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther (2013) 0.96
Chronic ethanol consumption modulates growth factor release, mucosal cytokine production, and microRNA expression in nonhuman primates. Alcohol Clin Exp Res (2013) 0.95
Progress and challenge of microRNA research in immunity. Front Genet (2014) 0.93
Critical role of microRNA-155 in herpes simplex encephalitis. J Immunol (2014) 0.89
MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med (2015) 0.88
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A (2014) 0.87
miR-155 is involved in Alzheimer's disease by regulating T lymphocyte function. Front Aging Neurosci (2015) 0.86
MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. Immunology (2015) 0.86
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol (2016) 0.84
microRNAs function in CD8+T cell biology. J Leukoc Biol (2015) 0.83
Engineering better immunotherapies via RNA interference. Hum Vaccin Immunother (2014) 0.82
The miRNA world of polyomaviruses. Virol J (2013) 0.82
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
MicroRNA Mechanisms of Action: What have We Learned from Mice? Front Genet (2015) 0.80
Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors. PLoS One (2014) 0.80
miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM Pathways. PLoS One (2015) 0.80
A microRNA profile of human CD8(+) regulatory T cells and characterization of the effects of microRNAs on Treg cell-associated genes. J Transl Med (2014) 0.79
MicroRNA regulation in human CD8+ T cell subsets--cytokine exposure alone drives miR-146a expression. J Transl Med (2014) 0.78
miR-150 Regulates Differentiation and Cytolytic Effector Function in CD8+ T cells. Sci Rep (2015) 0.78
Unexpected positive control of NFκB and miR-155 by DGKα and ζ ensures effector and memory CD8+ T cell differentiation. Oncotarget (2016) 0.78
Role of miR-155 in the pathogenesis of herpetic stromal keratitis. Am J Pathol (2015) 0.78
MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells. Sci Rep (2016) 0.77
Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77
HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepat (2016) 0.77
CD46 Activation Regulates miR-150-Mediated Control of GLUT1 Expression and Cytokine Secretion in Human CD4+ T Cells. J Immunol (2016) 0.77
miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. J Neuroinflammation (2016) 0.76
Identification of host miRNAs that may limit human rhinovirus replication. World J Biol Chem (2014) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Diacylglycerol Kinases in T Cell Tolerance and Effector Function. Front Cell Dev Biol (2016) 0.76
Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One (2014) 0.76
miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation. World J Gastroenterol (2016) 0.76
Involvement of eukaryotic small RNA pathways in host defense and viral pathogenesis. Viruses (2013) 0.76
Granulocyte colony-stimulating factor impairs CD8(+) T cell functionality by interfering with central activation elements. Clin Exp Immunol (2016) 0.76
Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy. Cancer Sci (2017) 0.75
Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity. Sci Rep (2017) 0.75
miR-155 releases the brakes on antitumor T cells. Oncoimmunology (2015) 0.75
Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies. World J Surg Oncol (2014) 0.75
MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. PLoS One (2016) 0.75
Dicer Regulates the Balance of Short-Lived Effector and Long-Lived Memory CD8 T Cell Lineages. PLoS One (2016) 0.75
Natural Functional SNPs in miR-155 Alter Its Expression Level, Blood Cell Counts, and Immune Responses. Front Immunol (2016) 0.75
A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J Exp Med (2016) 0.75
B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2017) 0.75
KLRG1 restricts memory T cell antitumor immunity. Oncotarget (2016) 0.75
miR-155: A Novel Target in Allergic Asthma. Int J Mol Sci (2016) 0.75
Noncoding RNAs and chronic inflammation: Micro-managing the fire within. Bioessays (2015) 0.75
miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. Sci Rep (2016) 0.75
MiR-21 is required for anti-tumor immune response in mice: an implication for its bi-directional roles. Oncogene (2017) 0.75
Curtailed T-cell activation curbs effector differentiation and generates CD8(+) T cells with a naturally-occuring memory stem cell phenotype. Eur J Immunol (2017) 0.75
miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. Cell Rep (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol (2003) 11.48
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 10.22
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
MicroRNA control in the immune system: basic principles. Cell (2009) 7.16
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
Aberrant T cell differentiation in the absence of Dicer. J Exp Med (2005) 6.58
Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med (2008) 5.97
miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature (2006) 5.05
MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 4.65
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2010) 4.56
Complete but curtailed T-cell response to very low-affinity antigen. Nature (2009) 4.31
The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97
Control of T cell viability. Annu Rev Immunol (2004) 3.89
A parsimonious model for gene regulation by miRNAs. Science (2011) 3.79
T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol (2002) 3.57
MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A (2011) 3.37
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
CD8(+) T cells: foot soldiers of the immune system. Immunity (2011) 2.45
B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem (2007) 2.44
IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol (2003) 2.42
High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2009) 2.42
Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol (2010) 2.12
Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity (2009) 2.04
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol (2007) 1.92
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol (2009) 1.89
Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev (2010) 1.85
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res (2007) 1.83
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood (2011) 1.80
Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene (2006) 1.69
MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. J Biol Chem (2010) 1.67
Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol (2010) 1.59
Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. Immunity (2003) 1.55
The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem (2010) 1.44
Dicer controls CD8+ T-cell activation, migration, and survival. Proc Natl Acad Sci U S A (2010) 1.43
Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem (2003) 1.38
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Regulation of B- and T-cell differentiation by a single microRNA. Biochem Soc Trans (2008) 1.25
Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. J Transl Med (2011) 1.13
IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J Immunol (2007) 1.11
SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential. J Exp Med (2005) 1.04
Selected microRNAs define cell fate determination of murine central memory CD8 T cells. PLoS One (2010) 1.02
Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors. Proc Natl Acad Sci U S A (2010) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
The Pathway Tools software. Bioinformatics (2002) 14.89
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol (2002) 5.75
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol (2005) 2.97
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol (2008) 2.87
Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79
Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood (2007) 2.78
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
A Role for cis Interaction between the Inhibitory Ly49A receptor and MHC class I for natural killer cell education. Immunity (2009) 2.62
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol (2007) 2.59
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 2.57
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol (2004) 2.40
TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat Immunol (2012) 2.37
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36